Vitreous fluorophotometry in diabetes mellitus.
Vitreous fluorophotometry has proved to be a useful method to evaluate the integrity of the blood-ocular barrier to fluorescein in clinical and experimental diabetes mellitus. Diabetic patients with or without background retinopathy had increased vitreous accumulation of fluorescein after intravenous injection when compared with age-matched controls. Streptozotocin-induced diabetes in rats increase vitreous fluorescein levels. In the rat, this abnormality was reversed with insulin therapy and with pancreatic islet transplantation. The breakdown of the blood-ocular barrier to fluorescein appears to be the earliest detectable ocular abnormality of diabetes.
D000328:Adult; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology* / Q000628:therapy; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis* / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000175:diagnosis* / Q000503:physiopathology; D005452:Fluoresceins / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation; D010783:Photometry / Q000295:instrumentation; D051381:Rats; D014184:Transplantation, Homologous; D014822:Vitreous Body / Q000032:analysis*
D005452:Fluoresceins; D007328:Insulin